论文部分内容阅读
21世纪肿瘤治疗学的最大进展是以受体及其介导的细胞信号传导为靶点的分子靶向治疗从实验室走向临床并取得令人瞩目的效果。突出表现是以表皮生长因子受体(epi-dermal growth factor receptor,EGFR)为靶点的靶向药物的临床应用。目前针对EGFR的治疗研究主要有[1]:①小分子酪氨
The greatest progress of oncology in the 21st century is that molecular targeted therapy targeting receptors and their mediated cell signaling goes from the laboratory to the clinic and achieves remarkable results. Highlighted is the clinical application of targeted drugs targeting epidermal growth factor receptor (EGFR). The current treatment of EGFR research mainly [1]: ① small molecule tyramine